1. One-pot Golden Gate Assembly of an avian infectious bronchitis virus reverse genetics system.
- Author
-
Bilotti K, Keep S, Sikkema AP, Pryor JM, Kirk J, Foldes K, Doyle N, Wu G, Freimanis G, Dowgier G, Adeyemi O, Tabatabaei SK, Lohman GJS, and Bickerton E
- Subjects
- Animals, Genome, Viral, Coronavirus Infections virology, Coronavirus Infections veterinary, Plasmids genetics, Poultry Diseases virology, Escherichia coli genetics, Infectious bronchitis virus genetics, Reverse Genetics methods
- Abstract
Avian infectious bronchitis is an acute respiratory disease of poultry of particular concern for global food security. Investigation of infectious bronchitis virus (IBV), the causative agent of avian infectious bronchitis, via reverse genetics enables deeper understanding of virus biology and a rapid response to emerging variants. Classic methods of reverse genetics for IBV can be time consuming, rely on recombination for the introduction of mutations, and, depending on the system, can be subject to genome instability and unreliable success rates. In this study, we have applied data-optimized Golden Gate Assembly design to create a rapidly executable, flexible, and faithful reverse genetics system for IBV. The IBV genome was divided into 12 fragments at high-fidelity fusion site breakpoints. All fragments were synthetically produced and propagated in E. coli plasmids, amenable to standard molecular biology techniques for DNA manipulation. The assembly can be carried out in a single reaction, with the products used directly in subsequent viral rescue steps. We demonstrate the use of this system for generation of point mutants and gene replacements. This Golden Gate Assembly-based reverse genetics system will enable rapid response to emerging variants of IBV, particularly important to vaccine development for controlling spread within poultry populations., Competing Interests: I have read the journal’s policy and the authors of the manuscript have the following competing interests: When performing this research and drafting this manuscript, KB, APS, JMP, SKT, and GJSL were employees of New England Biolabs, a manufacturer and vendor of molecular biology reagents including DNA ligases and Type IIS restriction enzymes. New England Biolabs funded the work and paid the salaries of these authors. This does not alter our adherence to PLOS ONE policies on sharing data and materials. A patent has previously been filed by The Pirbright Institute to protect the intellectual property of the work surrounding the mutations in nsp 10 and nsp 14 (Patent name: Coronavirus, Number EP3172319B1, Authors: Erica Bickerton, Sarah Keep, and Paul Britton). This does not alter our adherence to PLOS ONE policies on sharing data and materials., (Copyright: © 2024 Bilotti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF